Private equity firm Permira has officially initiated the sale of Neuraxpharm, a German pharmaceutical group. Lenders are preparing to provide up to $1.8 billion in acquisition financing, signaling a major healthcare buyout. Non-binding offers are expected by February 5th. Jefferies and JPMorgan are advising on the process, with Permira targeting proceeds between €3 billion and €4 billion.

Banks and private credit firms are vying to provide financing packages. The debt is expected to be structured primarily as senior leveraged loans. This competition reflects renewed confidence in leveraged finance markets after a rebound in M&A activity. The deal's success will depend on Neuraxpharm’s performance and the appetite of potential buyers.

Neuraxpharm's Ebitda last year ranged between €170 million and €200 million. Earnings are projected to reach approximately €230 million by 2026, driven by Briumvi, a drug for multiple sclerosis. Permira acquired Neuraxpharm in 2020 and has been exploring exit strategies since last year. This sale represents a significant opportunity.

The sale of Neuraxpharm is a key test of the current market's appetite for pharmaceutical deals. The outcome will be closely watched by investors. The deal will likely impact the broader healthcare sector. The final sale price will be a key indicator of the current valuation environment for these types of assets.